News Column

Manhattan Scientifics (MHTX) Announces Collaboration with MD Anderson Cancer Center to Validate New Instrument for Very Early Detection of Cancer

Page 2 of 1

ALBUQUERQUE, N.M.--(BUSINESS WIRE)-- Manhattan Scientifics (OTC: MHTX) executed an agreement to collaborate with The University of Texas MD Anderson Cancer Center (MDACC) to advance, demonstrate and validate a breakthrough technology developed by Edward R. Flynn, PhD, for the very early detection of cancer. Dr. Flynn is the founder and chief scientist of MHTX’s subsidiary, Senior Scientific LLC. Senior Scientific is seeking to commercialize this patented non-invasive technology using ultra-sensitive magnetic detectors to locate, identify and measure tumors thousands of times smaller than detectable using current technologies.

Manhattan Scientifics, Inc., together with the National Institute of Health, financed the development and construction of the new medical instrument that may become the next important evolutionary step in cancer diagnostics, which we believe will provide a dramatic advance beyond PET, MRI, CT and X-ray.

Senior Scientific selected MD Anderson to test the new system because of MD Anderson’s advanced cancer research facilities and the shared goal of bringing Senior Scientific’s technology from "bench to bedside.”

MD Anderson is collaborating with Senior Scientific to test the technology because of its potential to avoid false positives and provide the ability to detect cancer years earlier than other approaches. In many cancers, early detection is the key to cure.

Senior Scientific’s technology uses iron oxide nanoparticles and biomarkers to target specific cancer cell receptors. The instrument is used to rapidly magnetize, and then detect, the nanoparticles that have found cancer cells. The resulting measurement is specific to the targeted cells and is much more sensitive than existing technologies.

Following two years of informal collaboration, MD Anderson and Senior Scientific have now inked a deal to formally collaborate on this technology seeking a path toward FDA approval and human diagnostic applications. Under the collaboration agreement announced today, Senior Scientific will supply a next generation instrument to MD Anderson during the first quarter of 2014. MD Anderson will be the first institution to use the new technology in its cancer research programs.

Dr. Flynn said, "Cancer remains the second most common cause of death in the U.S., accounting for nearly one of every four deaths. Our formal collaboration with MD Anderson brings to fruition years of research from our MHTX team. I am excited to reach this important milestone which places our ground breaking technology into the skilled hands of the physicians and researchers at MDACC to help fight Cancer, the emperor of all maladies."

About Manhattan Scientifics

Manhattan Scientifics Inc. (www.mhtx.com, www.SeniorScientific.com) located in New Mexico, New York and Montreal, is focused on the commercialization of disruptive technologies in the nano-medicine space. It has achieved several critical milestones in the development of its proprietary technology for the very early detection of cancer. The company is also at work with its licensed NYSE "partner" to commercialize medical prosthetics applications for its patented ultra-fine-grain nanotechnology metals.

About MD Anderson

The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention. The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public. At MD Anderson, important scientific knowledge gained in the laboratory is rapidly translated to clinical care. Overall, MD Anderson's research program is considered one of the most productive efforts in the world aimed solely at cancer.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.





Manhattan Scientifics, Inc.

PR, IR, general information

Marvin Maslow, 917-923-3300

Email: marvin@mhtx.com

or

Corporate Advisory/PR

Fastnet Advisors:

Anthony Furey, 631-665-1234

Email: mtfurey@fastnetadvisors.com

or

Hawk Associates:

Frank Hawkins, 305-451-1888

Email: f.hawkins@hawkassociates.com

or

European Contact:

Herbert Strauss, +43-316-296-316

Email: herbert "at" eu-ir.com

or

Analyst:

SeeThruEquity, LLC

Ajay Tandon, 646-495-0939

Co-Founder and Director of Research

or

www.mhtx.com

www.seniorscientific.com


Source: Manhattan Scientifics Inc.


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Story Tools